menu
    • menu
    [{"orgOrder":0,"company":"CNX Therapeutics","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Partnership","leadProduct":"Nitrofurantoin","moa":"30S ribosomal S10","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CNX Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"CNX Therapeutics \/ Adalvo","highestDevelopmentStatusID":"15","companyTruncated":"CNX Therapeutics \/ Adalvo"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Nitrofurantoin","moa":"30S ribosomal S10","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Nitrofurantoin","moa":"30S ribosomal S10","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for NITROFURANTOIN MACROCRYSTALLINE

    Menu

    NITROFURANTOIN MACROCRYSTALLINE

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    CNX Therapeutics

    United Kingdom arrow
    Interphex
    Not Confirmed

    CNX Therapeutics

    United Kingdom arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nitrofurantoin

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved FDF

    Sponsor : Adalvo

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    CNX and Adalvo Sign Deal for Nitrofurantoin PR Commercialization

    Details :

    Product Name : Nitrofurantoin PR-Generic

    Product Type : Antibiotic

    Upfront Cash : Undisclosed

    December 16, 2024

    Lead Product(s) : Nitrofurantoin

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Sponsor : Adalvo

    Deal Size : Undisclosed

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    ANI Pharmaceuticals Inc

    U.S.A arrow
    Interphex
    Not Confirmed

    ANI Pharmaceuticals Inc

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nitrofurantoin

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    ANI Pharmaceuticals Announces the FDA Approval and Launch of Nitrofurantoin Oral Suspension USP

    Details : Nitrofurantoin is activated inside bacteria by reduction via the flavoprotein nitrofurantoin reductase to unstable metabolites, which disrupt ribosomal RNA, DNA and other intracellular components. It is bactericidal, especially to bacteria present in aci...

    Product Name : Furadantin-Generic

    Product Type : Antibiotic

    Upfront Cash : Inapplicable

    April 24, 2023

    Lead Product(s) : Nitrofurantoin

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Alembic Pharmaceuticals Limited

    India arrow
    Interphex
    Not Confirmed

    Alembic Pharmaceuticals Limited

    India arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nitrofurantoin

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Alembic Pharmaceuticals announces USFDA Final Approval for Nitrofurantoin Capsules, USP (Macrocrystals), 25 mg...

    Details : Nitrofurantoin capsules, USP (Macrocrystals) is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella an...

    Product Name : Undisclosed

    Product Type : Antibiotic

    Upfront Cash : Inapplicable

    January 07, 2021

    Lead Product(s) : Nitrofurantoin

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth